Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (16173)	1/11/2003 11:34:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Larry, has EVERYONE forgot what Amevive does to T cells???? I just can't imagine the FDA approving such a drug as Amevive which requires CONSTANT monitoring of T cells in a non-life threatening disease. The thing I like about Raptiva is there appears to be INSTANT recovery by stopping it. Once a fully informed patient easily UNDERSTANDS that if all you are doing is TRAFFICING instead of DESTRUCTION, just maybe a little jab Sub-Q once a week is the way to go. So, also it appears that Raptiva works rapidly AND only takes a little sub-Q jab once a week. NO NEED TO WORRY ABOUT T CELL DESTRUCTION!!!!!!!!!!! I can just see the possible ads now.....THIS IS YOUR T CELLS ON AMEVIVE.....SPLAT!!!!!!!!! Now this is your T cells on Raptiva........picture of a traffic cop confidently directing traffic. BTW, keep in mind that if BOTH are approved a physician both ethically and liability wise has to FULLY inform a patient about both. Can you imagine if a physician has a patient crash and burn on Amevive and didn't inform patient of the alternative treatments available at the time???? This includes making a possible switch IF the patient is on Amevive if approved and then IF Raptiva is approved later. What USUALLY happens when a patient is on one drug and another BETTER and SAFER drug is approved??? But hey, what do I know......I could be COMPLETELY wrong......only my humble opinions.

To: LarryS who wrote (16173)	1/20/2003 11:49:36 AM
From: Bluegreen	Respond to of 17367

HEY HEY HEY!!!!!!! DOUBLE DOSE!!!!!!! DOUBLE DOSE!!!!!!! IF YOU LIKED THE DOSE OF ENBREL FOR RHEUMATOID ARTHRITIS YOU'LL LOVE THE DOSE FOR PSORIASIS!!! What about LONG TERM safety at DOUBLE THE DOSE???? Have they done ANY LONG TERM studies of DOUBLE DOSE????? What can analysts on wall street be thinking????>>>>>>>>>>>>>>>>>Amgen arthritis drug effective against psoriasis By Deena Beasley and Jed Seltzer LOS ANGELES, Jan 17 (Reuters) - Amgen Inc. <AMGN.O> on Friday said a pivotal-stage trial shows that its arthritis drug Enbrel is also an effective treatment for psoriasis, a market which could dramatically expand the drug's sales potential. Amgen, the world's top biotechnology company, is racing Biogen Inc. <BGEN.O>, Johnson & Johnson <JNJ.N> and Genentech Inc. <DNA.N> to market the first effective treatment for the disorder characterized by red, scaly patches on the skin that affects more than 100 million people worldwide. By some estimates, the market for an effective psoriasis drug could reach $5 billion. Biogen has said it expects the U.S. Food and Drug Administration to approve in the first quarter of this year its application for Amevive, which works by targeting an immune system cell that plays a central role in the disease. Amgen has projected 2003 sales of Enbrel as high as $1.4 billion. The drug, which works by blocking a protein that causes inflammation, is approved for treatment of joint disorders rheumatoid arthritis and psoriatic arthritis. In the 600-patient Phase III trial, Enbrel improved psoriasis symptoms by at least 75 percent in nearly half of patients after 12 weeks of treatment, while nearly 60 percent achieved that goal after 24 weeks, Amgen said. Patients in the psoriasis trial were injected twice a week with double the amount of Enbrel, 50 milligrams, as the dose for which the drug is approved for rheumatoid arthritis patients. Side effects were similar to placebo pills, according to company spokeswoman Rebecca Hamm. She said full results from the trial will likely be presented in March at the annual meeting of the American Academy of Dermatology. Amgen will not, however, file for with the FDA for approval of Enbrel in psoriasis until results are in from a second Phase III trial of 600 patients. Those results are expected sometime later this year, Hamm said. Joel Sendek, an analyst at Lazard Freres & Co., said the Enbrel results compare favorably with data seen with other biologics. After 12 weeks of treatment, Biogen's Amevive was shown to be 75-percent effective in 21 percent of patients, while Genentech's Raptiva was shown to reach that goal in 23 percent of patients, he said in a report, while noting that it is difficult to compare the drugs without head-to-head studies. Shares of Amgen were up 30 cents, or 0.5 percent, at $51.48 in late Nasdaq trading, making it one of the only biotech companies in positive territory. Biogen saw its stock fall $3.24, or 7.8 percent, to $38.39 on Nasdaq, while shares of Genentech, which expects an FDA decision on Raptiva year by year-end, were down 37 cents at $38.84 on the New York Stock Exchange. 01/17/03 15:44 ET<<<<<<<<<<<<<<<<<<<<<